Author (Corporate) | European Medicines Agency |
---|---|
Series Title | Press Release |
Series Details | EMA/682305/2013 (07.11.13) |
Publication Date | 07/11/2013 |
Content Type | News |
The European Medicines Agency (EMA),on 7 November 2013, released an Addendum to the guideline on the evaluation of medicinal products indicated for the treatment of bacterial infections. One of the most important aspects of the addendum is that it outlines a new approach facilitating the development of antibacterial agents targeted against multidrug-resistant (MDR) pathogens where patients have very limited or no remaining treatment options. It also gives guidance on data-gathering strategies to support the benefit-risk evaluation as part of the marketing-authorisation process for different indications. |
|
Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001944.jsp&mid=WC0b01ac058004d5c1 |
Related Links |
|
Subject Categories | Health |
Countries / Regions | Europe |